Description
What is GHK‑Cu + BPC‑157 (20mg/5mg Blend)?
This co‑lyophilized research blend combines the copper tripeptide GHK‑Cu (20 mg) with the gastric protective peptide BPC‑157 (5 mg) for use in preclinical studies of dermal repair, hair follicle biology, and connective‑tissue remodeling. Each peptide has a distinct, complementary mechanism.
Mechanism of Action — Combined
- GHK‑Cu: Copper delivery, fibroblast activation, collagen/elastin/GAG synthesis, dermal papilla and follicle stimulation, broad gene‑expression modulation.
- BPC‑157: VEGF‑R2/eNOS upregulation, angiogenesis, gut‑barrier and tendon/ligament repair signaling.
- Combination rationale: GHK‑Cu drives extracellular matrix synthesis while BPC‑157 drives vascular ingrowth—two non‑overlapping arms of tissue regeneration.
Compound Properties
- Composition: GHK‑Cu 20 mg + BPC‑157 5 mg per vial
- Form: Lyophilized powder (blue/violet tint from Cu coordination)
- Unit size: 25 mg total / vial
- Source: Solid‑phase peptide synthesis; each peptide ≥98% purity by HPLC prior to blending
Research‑Reference Dosing
Published research‑reference ranges (for each constituent; no published blend‑specific PK):
- Pickart et al., Experimental Gerontology (2012, 2015): GHK‑Cu in dermal and systemic research.
- Sikiric et al., Current Pharmaceutical Design (2010): BPC‑157 in gut and musculoskeletal models.
- No published human clinical trial data exists for this specific blend.
Research Findings
- GHK‑Cu: collagen, elastin, and GAG synthesis; hair follicle anagen; broad gene‑expression modulation
- BPC‑157: tendon, ligament, muscle and gut healing in preclinical models
- Combined use is a common preclinical research protocol for skin and soft‑tissue regeneration studies
Known Side Effects Reported in Research/Trials
- Injection‑site erythema or mild burning (parenteral GHK‑Cu characteristic)
- Blue/green solution color from Cu coordination is normal
- Theoretical copper overload with prolonged high‑dose use
- Theoretical pro‑angiogenic caution in occult neoplasia
- Long‑term human safety data unavailable
Storage & Handling
- Lyophilized (unreconstituted) vials: store at −20°C long‑term; short‑term 2–8°C acceptable.
- After reconstitution with bacteriostatic or sterile water: store at 2–8°C; use within 14–28 days per standard peptide stability guidance.
- Protect from light, heat, and repeated freeze‑thaw cycles. Handle in a sterile laboratory environment.
Certificate of Analysis
A Certificate of Analysis (COA) confirming identity and purity by HPLC / MS is available upon request. Contact Lonestar Peptides for lot‑specific documentation.
Summaries reference peer‑reviewed preclinical and clinical literature available as of early 2025. Newer findings may not be reflected. Researchers should consult current literature and conduct their own due diligence. Lonestar Peptides makes no claim of therapeutic benefit.
